Vinorelbine

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc ATC codes: L01CA04

Indication	Rhabdomyosarcoma primary site ICD11 code: 2B55.Z
INN	Vinorelbine
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 10 mg per mL in 1 mL vial ; 10 mg per mL in 5 mL vial **Oral > Solid > capsule:** 20 mg ; 30 mg ; 80 mg (EML)
EML status history	First added in 2021 (TRS 1035) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Vinorelbine
DrugBank	Vinorelbine

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended deletion of vinorelbine 80 mg capsules from the EMLc, and modification of the description of the parenteral forms on the EML and EMLc to 10 mg/mL in 1 mL and 5 mL vials.